315P - Multinational survey study assessing genetic testing and counselling among patients (pts) with breast cancer (MAGENTA): Results on perceptions on testing

Background

Genetic testing (GT) is vital in the risk assessment of breast cancer (BC) and along with genetic counselling (GC), may inform treatment decisions. However, fewer than one-third of patients (pts) with BC undergo GT. A multinational survey was conducted for a deeper understanding of the barriers in the uptake of GT and GC. Results from this survey, focusing on awareness and pts’ perceptions towards GT and GC have been reported here.

Methods

A steering committee comprising of pts and pt advocates co-developed a 38-question online survey, which was launched in local languages for pts in Argentina, Australia, Brazil, Egypt, India, Malaysia, Mexico, Russia and Taiwan, through different social media platforms. The questions pathway was determined based on response to certain questions on GT & GC uptake. Percentage responses to a response option was calculated against the number of respondents for that question.

Results

The final analysis set (FAS) included responses from 1176 participants with more than 90% completion rate of survey questions. Median age among respondents in the FAS was 42 years (IQR: 35, 49) at the time of BC diagnosis. Among survey respondents, 63% (737/1176) had undergone GT, and 37% (439/1176) did not undergo GT. The table lists select questions on some aspects of the GT experience as well as perceptions of testing. Table: 315P

Conclusions

There are critical gaps in the awareness of GT among pts and the public, along with gaps in perceived value and access to GT, with notable variance between the tested and the non-tested populations. Strategic action is needed to overcome the barriers to GT and to improve the pt experience.

Clinical trial identification

Editorial acknowledgement

Professional medical writing assistance was provided by Madhubrata Ghosh, PhD, of Ward6 Singapore Pte Ltd, Singapore, and funded by AstraZeneca.

Legal entity responsible for the study

AstraZeneca UK Limited.

Funding

AstraZeneca International (AstraZeneca UK limited).

Disclosure

S.L. Powell: Financial Interests, Personal, Full or part-time Employment: Pink Hope; Financial Interests, Personal, Advisory Board, Honoraria: AstraZeneca; Non-Financial Interests, Personal, Other, Travel support: AstraZeneca. M. Artigas: Financial Interests, Personal, Advisory Board, Honoraria: AstraZeneca. I. Borovova: Financial Interests, Personal, Full or part-time Employment: Russian Association of Oncology Patients “ZDRAVSTVUY!”; Financial Interests, Personal, Advisory Board: Public Council under the Ministry of Health of the Russian Federation, Presidential Council for the Development of Civil Society and Human Rights, Public Council under Roszdravnadzor, Council for Social Welfare under the Government of the Russian Federation; Financial Interests, Personal, Advisory Board, Honoraria: AstraZeneca. P. Gadiya: Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Advisory Role: AstraZeneca. A. Hsu: Financial Interests, Personal, Advisory Board: AstraZeneca. R. Kaur: Financial Interests, Personal, Advisory Board: Pfizer, Novartis, Roche, AstraZeneca; Financial Interests, Personal, Invited Speaker: Pfizer, Novartis, Roche, AstraZeneca; Financial Interests, Personal, Research Grant: Pfizer, Novartis, Roche, AstraZeneca; Financial Interests, Institutional, Other: Pfizer, Novartis, Roche, AstraZeneca; Financial Interests, Personal, Advisory Board, Honoraria: Pfizer, Novartis, Roche, AstraZeneca; Financial Interests, Personal, Other, Congress participation, travel support, lectures: Pfizer, Novartis, Roche; Financial Interests, Personal, Training: Pfizer, Novartis, Roche; Financial Interests, Personal, Advisory Role: Pfizer, Novartis, Roche; Financial Interests, Personal, Speaker, Consultant, Advisor: Pfizer, Novartis, Roche, AstraZeneca; Financial Interests, Personal, Advisory Board, Congress participation, lectures: AstraZeneca. L. Kidd: Financial Interests, Personal, Full or part-time Employment: Victorian Department of Education, Beaconsfield Primary School; Financial Interests, Personal, Advisory Board, Honoraria: AstraZeneca. D. Rosenfeld: Financial Interests, Personal, Advisory Board, Honoraria: AstraZeneca. M.M. Saeed: Financial Interests, Personal, Advisory Board, Honoraria: AstraZeneca. E. Scarelli: Financial Interests, Personal, Full or part-time Employment: OncoGuia Institute; Financial Interests, Personal, Advisory Board: AstraZeneca, Pfizer, Roche, Novartis, MSD, MSD, Daiichi Sankyo, Bayer; Financial Interests, Personal, Advisory Board, Honoraria: AstraZeneca, Pfizer, Roche, Novartis, MSD, Daiichi Sankyo, Bayer; Financial Interests, Personal, Other, Congress participation, lectures: AstraZeneca, Roche, Novartis, Daiichi Sankyo, Bayer; Financial Interests, Personal, Invited Speaker: AstraZeneca, Pfizer, Roche, Novartis, Daiichi Sankyo, Bayer; Financial Interests, Personal, Advisory Board, Congress participation, lectures: Pfizer, MSD. M. Wahib: Financial Interests, Personal, Full or part-time Employment: AstraZeneca; Financial Interests, Personal, Stocks/Shares: AstraZeneca.